Table 2.
HR | 95% CI | p-value | |
---|---|---|---|
All Subjects (N=6540)* | |||
CAC Group | |||
0 | 1.0 | ||
1-100 | 4.4 | 2.6 – 7.5 | <0.001 |
101-400 | 9.8 | 5.8 – 16.8 | <0.001 |
>400 | 17.5 | 10.1 – 30.3 | <0.001 |
# of vessels with CAC | |||
0 | 1.0 | ||
1 | 2.6 | 1.4 – 4.8 | 0.004 |
2 | 7.0 | 4.0 – 12.3 | <0.001 |
3 | 12.2 | 7.2 – 20.7 | <0.001 |
4 | 16.8 | 9.6 – 29.6 | <0.001 |
Subjects with CAC>0 (N=3259)** | |||
# of vessels with CAC | |||
1 | 1.0 | ||
2 | 2.5 | 1.5 – 4.4 | 0.001 |
3 | 3.4 | 1.9 – 6.0 | <0.001 |
4 | 4.1 | 2.2 – 7.7 | <0.001 |
Model adjusted for age, gender, race/ethnicity, diabetes, smoking, hypertension, LDL-C, HDL-C, triglycerides, CRP, family history, anti-hypertensive medication use, lipid-lowering medication use, education level, and MESA study site.
Model additionally adjusted for CAC group (1-100, 101-400, >400)